RER1 Stock Overview
Researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Recordati Industria Chimica e Farmaceutica S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €50.60 |
| 52 Week High | €60.00 |
| 52 Week Low | €44.12 |
| Beta | 0.53 |
| 1 Month Change | 4.33% |
| 3 Month Change | -6.38% |
| 1 Year Change | 7.43% |
| 3 Year Change | 23.90% |
| 5 Year Change | 19.28% |
| Change since IPO | 75.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| RER1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.1% | 2.0% | -0.9% |
| 1Y | 7.4% | -25.8% | 14.1% |
Return vs Industry: RER1 exceeded the German Pharmaceuticals industry which returned -26.3% over the past year.
Return vs Market: RER1 underperformed the German Market which returned 15.8% over the past year.
Price Volatility
| RER1 volatility | |
|---|---|
| RER1 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: RER1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: RER1's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 4,539 | Rob Koremans | recordati.com |
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops REC 0545 for acute decompensation in maple syrup urine diseases; Isturia for endogenous Cushing’s syndrome; Cystadrops for corneal cystine crystal deposits; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fortivda for renal cell carcinoma.
Recordati Industria Chimica e Farmaceutica S.p.A. Fundamentals Summary
| RER1 fundamental statistics | |
|---|---|
| Market cap | €10.59b |
| Earnings (TTM) | €417.95m |
| Revenue (TTM) | €2.41b |
Is RER1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RER1 income statement (TTM) | |
|---|---|
| Revenue | €2.41b |
| Cost of Revenue | €732.70m |
| Gross Profit | €1.68b |
| Other Expenses | €1.26b |
| Earnings | €417.95m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 29, 2025
| Earnings per share (EPS) | 2.03 |
| Gross Margin | 69.64% |
| Net Profit Margin | 17.32% |
| Debt/Equity Ratio | 117.2% |
How did RER1 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 05:07 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Recordati Industria Chimica e Farmaceutica S.p.A. is covered by 26 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paola Saglietti | Banca Akros S.p.A. (ESN) |
| Charles Pitman | Barclays |
| Nicolas Guyon-Gellin | BNP Paribas Exane |